Figure 1



*
0.06
0.05
0.04
0.03
0.02
0.01
0
Declines in Gait Speed (m/s)
1st (-)
2nd
3rd (+)
Δ Thigh Muscle Area
3rd (+)
2nd
1st (-)
Δ Thigh Intermuscular Fat Area

Figure 2.



PBS
Propeptide
BYM338
Body weight change (g)
days
muscle/tibial body weight
(% change from control)
% frequency
fiber area in µm²

Figure 3.



Hind limb muscle volume (mL)
5.5
5.0
4.5
4.0
3.5
3.0
+2%
+1%
+13%
+12%
+7%
+0%
0
7
14
21
Days
6 mths / IgG1
6 mths / BYM338
21 mths / IgG1
21 mths / BYM338

Figure 4.



* P<0.01
TKV Change from screening (Pre-Cast)(%)
6
4
2
0
-2
-4
*
*
*
*
Scr (Pre-Cast)
Bas (Post-Cast)
Week 2
Week 4
EOS (Week 12)
30 mg/kg BYM338
Placebo

Figure 5.



TMV Change from baseline (%)
8
6
4
2
0
N=16
N=16
*
BAS
W2D15
W4D29
W8D57
W16D113
30mg/kg BYM338
Placebo

Figure 6.



BMAT Change from baseline (%)
D-3
W2
W4
W10
0.1mg/kg BYM338
0.3mg/kg BYM338
1mg/kg BYM338
3mg/kg BYM338
10mg/kg BYM338
30mg/kg BYM338
Placebo

Figure 7.





Figure 8.


Post-treatment follow up 4 weeks
Treatment epoch – 12 months
BYM338 700 mg i.v. 13 doses
BYM338 210 mg i.v. 13 doses
BYM338 70 mg i.v. 13 doses
Placebo i.v. 13 doses
Screening epoch – 5 weeks
surgery
D7
D14-D42 Randomization
End of study analysis (all patients completed)
W24 (Primary & secondary endpoint analysis)
W56 (end of study)
W52 (end of treatment)